Tags

Type your tag names separated by a space and hit enter

Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA.
Am J Obstet Gynecol 2014; 211(4):365.e1-12AJ

Abstract

OBJECTIVE

The objective of this study was to validate the clinical performance of massively parallel genomic sequencing of cell-free deoxyribonucleic acid contained in specimens from pregnant women at high risk for fetal aneuploidy to test fetuses for trisomies 21, 18, and 13; fetal sex; and the common sex chromosome aneuploidies (45, X; 47, XXX; 47, XXY; 47, XYY).

STUDY DESIGN

This was a prospective multicenter observational study of pregnant women at high risk for fetal aneuploidy who had made the decision to pursue invasive testing for prenatal diagnosis. Massively parallel single-read multiplexed sequencing of cell-free deoxyribonucleic acid was performed in maternal blood for aneuploidy detection. Data analysis was completed using sequence reads unique to the chromosomes of interest.

RESULTS

A total of 3430 patients were analyzed for demographic characteristics and medical history. There were 137 fetuses with trisomy 21, 39 with trisomy 18, and 16 with trisomy 13 for a prevalence rate of the common autosomal trisomies of 5.8%. There were no false-negative results for trisomy 21, 3 for trisomy 18, and 2 for trisomy 13; all 3 false-positive results were for trisomy 21. The positive predictive values for trisomies 18 and 13 were 100% and 97.9% for trisomy 21. A total of 8.6% of the pregnancies were 21 weeks or beyond; there were no aneuploid fetuses in this group. All 15 of the common sex chromosome aneuploidies in this population were identified, although there were 11 false-positive results for 45,X. Taken together, the positive predictive value for the sex chromosome aneuploidies was 48.4% and the negative predictive value was 100%.

CONCLUSION

Our prospective study demonstrates that noninvasive prenatal analysis of cell-free deoxyribonucleic acid from maternal plasma is an accurate advanced screening test with extremely high sensitivity and specificity for trisomy 21 (>99%) but with less sensitivity for trisomies 18 and 13. Despite high sensitivity, there was modest positive predictive value for the small number of common sex chromosome aneuploidies because of their very low prevalence rate.

Authors+Show Affiliations

Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Presbyterian/St Luke's Medical Center, Obstetrix Medical Group of Colorado, Denver, CO. Electronic address: richard_porreco@pediatrix.com.University of California, Irvine, Orange, CA, and Pediatrix/Obstetrix Medical Group, Inc, Sunrise, FL/Perigen Inc, Princeton, NJ.Pediatrix/Obstetrix Medical Group, Inc, Sunrise, FL.Pediatrix/Obstetrix Medical Group, Inc, Sunrise, FL.No affiliation info availableSequemon, Inc, San Diego, CA.Sequemon, Inc, San Diego, CA.Sequemon, Inc, San Diego, CA.Sequemon, Inc, San Diego, CA.

Pub Type(s)

Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Validation Studies

Language

eng

PubMed ID

24657131

Citation

Porreco, Richard P., et al. "Noninvasive Prenatal Screening for Fetal Trisomies 21, 18, 13 and the Common Sex Chromosome Aneuploidies From Maternal Blood Using Massively Parallel Genomic Sequencing of DNA." American Journal of Obstetrics and Gynecology, vol. 211, no. 4, 2014, pp. 365.e1-12.
Porreco RP, Garite TJ, Maurel K, et al. Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. Am J Obstet Gynecol. 2014;211(4):365.e1-12.
Porreco, R. P., Garite, T. J., Maurel, K., Marusiak, B., Ehrich, M., van den Boom, D., ... Bombard, A. (2014). Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. American Journal of Obstetrics and Gynecology, 211(4), pp. 365.e1-12. doi:10.1016/j.ajog.2014.03.042.
Porreco RP, et al. Noninvasive Prenatal Screening for Fetal Trisomies 21, 18, 13 and the Common Sex Chromosome Aneuploidies From Maternal Blood Using Massively Parallel Genomic Sequencing of DNA. Am J Obstet Gynecol. 2014;211(4):365.e1-12. PubMed PMID: 24657131.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Noninvasive prenatal screening for fetal trisomies 21, 18, 13 and the common sex chromosome aneuploidies from maternal blood using massively parallel genomic sequencing of DNA. AU - Porreco,Richard P, AU - Garite,Thomas J, AU - Maurel,Kimberly, AU - Marusiak,Barbara, AU - ,, AU - Ehrich,Mathias, AU - van den Boom,Dirk, AU - Deciu,Cosmin, AU - Bombard,Allan, Y1 - 2014/03/19/ PY - 2014/01/25/received PY - 2014/03/06/revised PY - 2014/03/17/accepted PY - 2014/3/25/entrez PY - 2014/3/25/pubmed PY - 2014/12/15/medline KW - cell-free deoxyribonucleic acid KW - massively parallel genomic sequencing KW - noninvasive prenatal screening SP - 365.e1 EP - 12 JF - American journal of obstetrics and gynecology JO - Am. J. Obstet. Gynecol. VL - 211 IS - 4 N2 - OBJECTIVE: The objective of this study was to validate the clinical performance of massively parallel genomic sequencing of cell-free deoxyribonucleic acid contained in specimens from pregnant women at high risk for fetal aneuploidy to test fetuses for trisomies 21, 18, and 13; fetal sex; and the common sex chromosome aneuploidies (45, X; 47, XXX; 47, XXY; 47, XYY). STUDY DESIGN: This was a prospective multicenter observational study of pregnant women at high risk for fetal aneuploidy who had made the decision to pursue invasive testing for prenatal diagnosis. Massively parallel single-read multiplexed sequencing of cell-free deoxyribonucleic acid was performed in maternal blood for aneuploidy detection. Data analysis was completed using sequence reads unique to the chromosomes of interest. RESULTS: A total of 3430 patients were analyzed for demographic characteristics and medical history. There were 137 fetuses with trisomy 21, 39 with trisomy 18, and 16 with trisomy 13 for a prevalence rate of the common autosomal trisomies of 5.8%. There were no false-negative results for trisomy 21, 3 for trisomy 18, and 2 for trisomy 13; all 3 false-positive results were for trisomy 21. The positive predictive values for trisomies 18 and 13 were 100% and 97.9% for trisomy 21. A total of 8.6% of the pregnancies were 21 weeks or beyond; there were no aneuploid fetuses in this group. All 15 of the common sex chromosome aneuploidies in this population were identified, although there were 11 false-positive results for 45,X. Taken together, the positive predictive value for the sex chromosome aneuploidies was 48.4% and the negative predictive value was 100%. CONCLUSION: Our prospective study demonstrates that noninvasive prenatal analysis of cell-free deoxyribonucleic acid from maternal plasma is an accurate advanced screening test with extremely high sensitivity and specificity for trisomy 21 (>99%) but with less sensitivity for trisomies 18 and 13. Despite high sensitivity, there was modest positive predictive value for the small number of common sex chromosome aneuploidies because of their very low prevalence rate. SN - 1097-6868 UR - https://www.unboundmedicine.com/medline/citation/24657131/Noninvasive_prenatal_screening_for_fetal_trisomies_21_18_13_and_the_common_sex_chromosome_aneuploidies_from_maternal_blood_using_massively_parallel_genomic_sequencing_of_DNA_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9378(14)00270-1 DB - PRIME DP - Unbound Medicine ER -